Synopsis
Synopsis
0
VMF
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2(1h)-isoquinolinecarboxylic Acid, 3,4-dihydro-1-phenyl-,1- Azabicyclo(2.2.2)oct-3-yl Ester, (r-(r*,s*))-
2. 905, Ym
3. Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate Monosuccinate
4. Solifenacin
5. Succinate, Solifenacin
6. Vesicare
7. Ym 905
8. Ym905
1. 242478-38-2
2. Vesicare
3. Solifenacin (succinate)
4. Solifenacin Succinate [usan]
5. Ym-905
6. Ym 905
7. Ym905
8. 1-azabicyclo[2.2.2]octan-8-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Butanedioic Acid
9. Ym67905
10. Kka5dld701
11. Ym-67905
12. [(3r)-1-azabicyclo[2.2.2]octan-3-yl] (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate;butanedioic Acid
13. Vesikur
14. (s)-(r)-quinuclidin-3-yl 1-phenyl-3,4-dihydroisoquinoline-2(1h)-carboxylate Succinate
15. Chembl1200803
16. Solifenacin Succinate Salt
17. Unii-kka5dld701
18. Vesicare Od
19. Vesicare (tn)
20. Isoprenalinoe Sulfate
21. Vesicare Ls
22. Solifenacin Succinate- Bio-x
23. Mls006010416
24. Schembl109333
25. Chebi:32151
26. Dtxsid30947075
27. Hms3887a13
28. Solifenacin Succinate [mi]
29. Solifenacin Succinate [jan]
30. Ex-a4170
31. Hy-a0002
32. Mfcd00954234
33. S3048
34. Solifenacin Succinate [vandf]
35. Solifenacin Succinate [mart.]
36. Akos015994745
37. Solifenacin Succinate [usp-rs]
38. Solifenacin Succinate [who-dd]
39. Am84825
40. Ccg-269551
41. Cs-0371
42. Ks-1286
43. Solifenacin Succinate (jan/usan/inn)
44. Solifenacin Succinate, >=98% (hplc)
45. [(3r)-1-azabicyclo[2.2.2]octan-3-yl] (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate; Butanedioic Acid
46. 2(1h)-isoquinolinecarboxylic Acid, 3,4-dihydro-1-phenyl-, (3r)-1-azabicyclo(2.2.2)oct-3-yl Ester, (1s)-, Butanedioate (1:1)
47. As-35288
48. Bs164410
49. Butanedioic Acid, Cmpd. With (1s)-(3r)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1h)-isoquinolinecarboxylate (1:1)
50. Butanedioic Acid, Compd With (1s)-(3r)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1h)-isoquinolinecarboxylate (1:1)
51. Smr004701445
52. Ym-53705
53. Solifenacin Succinate [orange Book]
54. Solifenacin Succinate [ep Monograph]
55. S0944
56. Sw219141-1
57. D01269
58. A819262
59. A881133
60. Q374826
61. Solifenacin Succinate, Europepharmacopoeia (ep) Reference Standard
62. Solifenacin Succinate, United States Pharmacopeia (usp) Reference Standard
63. (r)-quinuclidin-3-yl (s)-1-phenyl-3,4-dihydroisoquinoline-2(1h)-carboxylate
64. (s)-(r)-quinuclidin-3-yl1-phenyl-3,4-dihydroisoquinoline-2(1h)-carboxylatesuccinate
65. Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylatemonosuccinate
66. Solifenacin For System Suitability, Europepharmacopoeia (ep) Reference Standard
67. (1s)-(3r)-1-azabicyclo[2.2.2]oct-3-yl-3,4-dihydro-1-phenyl-2(1h)-isoquinolinecarboxylate Succinate
68. 1-azabicyclo[2.2.2]octan-8-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Butanedioic Acid (solifenacin?succinate)
69. Butanedioic Acid--1-azabicyclo[2.2.2]octan-3-yl 1-phenyl-3,4-dihydroisoquinoline-2(1h)-carboxylate (1/1)
70. Butanedioic Acid; (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylic Acid [(3r)-1-azabicyclo[2.2.2]octan-3-yl] Ester
Molecular Weight | 480.6 g/mol |
---|---|
Molecular Formula | C27H32N2O6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 6 |
Exact Mass | 480.22603674 g/mol |
Monoisotopic Mass | 480.22603674 g/mol |
Topological Polar Surface Area | 107 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 617 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Solifenacin succinate |
Drug Label | VESIcare (solifenacin succinate) is a muscarinic receptor antagonist. Chemically, solifenacin succinate is butanedioic acid, compounded with (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-iso-quinolinecarboxylate (1:1) having an e... |
Active Ingredient | Solifenacin succinate |
Dosage Form | Tablet |
Route | Oral |
Strength | 5mg; 10mg |
Market Status | Prescription |
Company | Teva Pharms Usa |
2 of 4 | |
---|---|
Drug Name | Vesicare |
PubMed Health | Solifenacin (By mouth) |
Drug Classes | Urinary Antispasmodic |
Drug Label | VESIcare (solifenacin succinate) is a muscarinic receptor antagonist. Chemically, solifenacin succinate is butanedioic acid, compounded with (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-iso-quinolinecarboxylate (1:1) having an e... |
Active Ingredient | Solifenacin succinate |
Dosage Form | Tablet |
Route | Oral |
Strength | 5mg; 10mg |
Market Status | Prescription |
Company | Astellas |
3 of 4 | |
---|---|
Drug Name | Solifenacin succinate |
Drug Label | VESIcare (solifenacin succinate) is a muscarinic receptor antagonist. Chemically, solifenacin succinate is butanedioic acid, compounded with (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-iso-quinolinecarboxylate (1:1) having an e... |
Active Ingredient | Solifenacin succinate |
Dosage Form | Tablet |
Route | Oral |
Strength | 5mg; 10mg |
Market Status | Prescription |
Company | Teva Pharms Usa |
4 of 4 | |
---|---|
Drug Name | Vesicare |
PubMed Health | Solifenacin (By mouth) |
Drug Classes | Urinary Antispasmodic |
Drug Label | VESIcare (solifenacin succinate) is a muscarinic receptor antagonist. Chemically, solifenacin succinate is butanedioic acid, compounded with (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-iso-quinolinecarboxylate (1:1) having an e... |
Active Ingredient | Solifenacin succinate |
Dosage Form | Tablet |
Route | Oral |
Strength | 5mg; 10mg |
Market Status | Prescription |
Company | Astellas |
Treatment of neurogenic detrusor overactivity
Urological Agents
Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?